NFKB1 and mantle cell lymphoma: Rudelius et al. demonstrated that ibrutinib and FAK inhibition were highly synergistic in mantle cell lymphoma, reporting complete abrogation of NF-κB signaling pathway, even in ibrutinib resistant cells [47].